Monopar Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Monopar Therapeutics

05/08/2025 14:16

Monopar Therapeutics Inc MNPR.OQ MNPR.O is expected to  show no change in quarterly revenue when it reports  results on August 7 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Monopar Therapeutics Inc is for a loss of 47 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Monopar Therapeutics Inc is $71.00, about 41.2% above its last closing price of $41.75

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.69
-0.68
-0.38
Beat
44.1
Dec. 31 2025
-0.42
-2.75
Missed
-554.8
Sep. 30 2024
-0.48
-0.48
-0.37
Beat
22.4​
Jun. 30 2024
-0.47
-0.47
-0.50
Missed
-7.1
​​Mar. 31 2024
-0.60
-0.60
-0.50
Beat
16.7
Dec. 31 2023
-0.77
-0.60
Beat
22.6​
Sep. 30 2023
-0.75
-0.85
-0.70
Beat
17.6
Jun. 30 2023
-0.89
-0.92
-0.80
Beat
13

This summary was machine generated August 5 at 13:16 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)